PLAU and nonpapillary renal cell carcinoma: Thus, a pronounced additive effect on prognosis of pT1+2 ccRCC patients, i.e. patients with an assumed lower risk of cancer-related death, was identified when combining uPA and uPAR antigen levels in tumour tissue.